Casirivimab-imdevimab treatment is associated with reduced rates of mortality and hospitalization in patients with COVID-19: A systematic review with meta-analysis

Gao, Ming; Ao, Guangyu; Hao, Xiaodan; Xie, Bin

doi:10.1016/j.jinf.2023.04.019

Cited by 5 publications

(1 citation statement)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This breadth facilitated robust subgroup analyses. Another meta-analysis ( 45 ) with limited study populations only studied the efficacy of casirivimab and imdevimab in COVID-19 patients and showed that the drug reduced the hospitalization rate and mortality rate of COVID-19 patients, consistent with our study. However, the study indicators were more homogeneous, and our study also studied the viral load, death and mechanical ventilation rate, all-cause mortality rate, infection rate, discharge rate, and emergency room visits on this basis.…”

Section: Discussionsupporting

confidence: 89%

Efficacy and safety of casirivimab and imdevimab for preventing and treating COVID-19: a systematic review and meta-analysis

Cui,

Wang,

Zou

et al. 2024

J Thorac Dis

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 89%

Efficacy and safety of casirivimab and imdevimab for preventing and treating COVID-19: a systematic review and meta-analysis

Cui,

Wang,

Zou

et al. 2024

J Thorac Dis

View full text Add to dashboard Cite

Efficacy and safety of therapies for COVID-19 in pregnancy: a systematic review and meta-analysis

Di Gennaro,

Guido,

Frallonardo

et al. 2023

BMC Infect Dis

View full text Add to dashboard Cite

Background Clinical evidence suggests that pregnant women are more vulnerable to COVID-19, since they are at increased risk for disease progression and for obstetric complications, such as premature labor, miscarriage, preeclampsia, cesarean delivery, fetal growth restriction and perinatal death. Despite this evidence, pregnant women are often excluded from clinical trials, resulting in limited knowledge on COVID-19 management. The aim of this systematic review and meta-analysis is to provide better evidence on the efficacy and safety of available COVID-19 treatment in pregnant women. Methods Four authors searched major electronic databases from inception until 1 st November-2022 for controlled trials/observational studies, investigating outcomes after the administration of anti-SARS-CoV-2 treatments in pregnant women affected by COVID-19. The analyses investigated the cumulative incidence of delivery and maternal outcomes in pregnant women, comparing those taking active medication vs standard care. Risk ratios (RRs) with 95% confidence intervals were calculated. Statistical significance was assessed using the random effects model and inverse-variance method. This systematic review and meta-analysis was conducted in accordance with the updated 2020 Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The protocol has been registered in Prospero (number registration: CRD42023397445). Results From initially 937 non duplicate records, we assessed the full texts of 40 articles, finally including ten studies. In six studies, including 1627 patients, the use of casirivimab/imdevimab (CAS/IMD), remdesivir, and IFN-alpha 2b significantly decreased the need of cesarean section ((RR = 0.665; 95%CI: 0.491–0.899; p = 0.008; I 2 = 19.5%;) (Table 1, (Fig. 1). Treatments did not decrease the risk of preterm delivery, admission to neonatal ICU, or stillbirth/perinatal loss (p-values > 0.50 for all these outcomes) and did not prevent the progression of disease towards severe degrees (k = 8; 2,374 pregnant women; RR = 0.778; 95%CI: 0.550–1.099; p = 0.15; I 2 = 0%). Moreover, the use of medications during pregnancy did not modify the incidence of maternal death in two studies (Table 2). Conclusions To our analysis, CAS/IMD, remdesivir, and IFN alpha 2b reduced the number of cesarean sections but demonstrated no effect on disease progression and other obstetric and COVID-19 related outcomes. The inability to evaluate the influence of viral load on illness development in pregnant women was attributed to lack of data. In our systematic review, no major side effects were reported. Though, it is essential for the medical community to focus more on clinical trials and less on episodic case reports and case series, with standardization of fetal and maternal outcomes.

show abstract

Clinical Effectiveness of Casirivimab and Imdevimab Compared With Standard of Care in Covid-19: A Systematic Review and Meta-Analysis

Orandi,

Mohajeri,

Mansouri

et al. 2024

Studies in Medical Sciences

View full text Add to dashboard Cite

Casirivimab-imdevimab treatment is associated with reduced rates of mortality and hospitalization in patients with COVID-19: A systematic review with meta-analysis

Cited by 5 publications

References 10 publications

Efficacy and safety of casirivimab and imdevimab for preventing and treating COVID-19: a systematic review and meta-analysis

Efficacy and safety of casirivimab and imdevimab for preventing and treating COVID-19: a systematic review and meta-analysis

Efficacy and safety of therapies for COVID-19 in pregnancy: a systematic review and meta-analysis

Clinical Effectiveness of Casirivimab and Imdevimab Compared With Standard of Care in Covid-19: A Systematic Review and Meta-Analysis

Contact Info

Product

Resources

About